医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar

2018年02月09日 PM10:00
このエントリーをはてなブックマークに追加


 

NEW HAVEN, Conn.

The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy. He will provide expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through to final analysis. Dr. Edgar will also be a key advisor to Cogstate’s commercial and product teams for the development of new technologies and approaches in line with industry needs.

“It’s with great excitement that we welcome Dr. Edgar to our scientific leadership team,” said Brad O’Connor, Cogstate CEO. “He brings valuable expertise to our customers and joins us at a pivotal time as we continue to expand our support of clinical trials with disruptive approaches to rater training, eSource solutions and computerized cognitive assessment; and CognigramTM for Healthcare.”

Dr. Edgar joins Cogstate from Roche where he oversaw clinical endpoint strategy for multiple neuroscience indications in the Patient-Centered Outcomes Research group. He holds a PhD in psychopharmacology from Northumbria University and has nearly two decades of pharmaceutical industry experience.

Dr. Edgar has held other strategic positions including clinical scientist at Roche on Schizophrenia and Alzheimer’s disease drug development programs, senior clinical lead for rater training and data quality at Bracket, and scientific director at Cognitive Drug Research Ltd., a computerized cognitive assessment company. Dr. Edgar is also a respected consultant to numerous pharmaceutical companies. His current research interests include defining clinically meaningful progression and meaningful change estimates in neurodegenerative disease, cognitive screening for Alzheimer’s disease, application of survival analysis to neuroscience clinical trials, defining treatment benefit for negative symptoms associated with schizophrenia and measurement science topics relevant to regulators.

About Cogstate

Cogstate Ltd (ASX:CGS) is a leading science and technology solutions provider dedicated to optimizing the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides enabling technologies and professional services for higher quality neuropsychological assessments and is a pioneer in commercializing rapid, reliable and highly sensitive computerized cognitive tests. Cogstate customers include the world’s leading biopharmaceutical companies; elite sporting organizations and military; physicians and patients; renowned academic institutions and public-private partnerships. For more information, please visit www.cogstate.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180209005125/en/

CONTACT

Cogstate
Rachel Colite, 203-773-5010
rcolite@cogstate.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
  • Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease
  • Quantapore Inc. Closes Series 3 Financing Round to Fund Beta Launch of DNA Sequencer
  • Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA®
  • Samsung BioLogics Streamlines Quality Document Management Globally With Veeva Vault QualityDocs